Lowenstein represented Playground Global, an early-stage venture capital firm that invests in deep tech and assists startups with software, hardware, machine learning, marketing, talent and design, in the closing of a $12 million seed round for Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development. Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier also participated in the round.
Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. Infinimmune will deploy its holistic approach to build its own pipeline of drug candidates and partner with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications.
The deal team included Carl J. Hessler, Mark P. Kesslen, Ed Zimmerman, Carmen C. DeMatteis, Oluwaseyi O. Amorin, Gwendolyn Holst, and Chynara Tolubaeva.
